TRPM8 Inhibitors
1 drugsAbout TRPM8
TRPM8, or transient receptor potential cation channel subfamily M member 8, is an ion channel that acts as a cellular sensor for cold temperatures and cooling compounds like menthol, playing a crucial role in cellular signaling.
Currently, there is no genetic evidence directly linking TRPM8 to specific diseases, suggesting further research is needed to fully understand its role in disease pathology.
TRPM8 is targeted by one FDA-approved small molecule drug, TRYPTYR (Novartis), indicated for ophthalmology, with approvals in 2025.
Top TRPM8 Drugs
Novartis is the only company with an approved drug targeting TRPM8.
The limited number of players suggests a potential opportunity for new entrants in the TRPM8 therapeutic space.
TRPM8 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TRPM8, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage in targeting TRPM8.
TRPM8 Clinical Trials 11 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TRPM8. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 4 | 11 | 0 | 0 | 11 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TRPM8 Drug Approval Timeline (2025 - 2025)
The first and most recent drug approval for TRPM8 was TRYPTYR in 2025.
The recent approval suggests renewed interest in TRPM8, but further approvals are needed to confirm sustained therapeutic value.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TRPM8. A trial counts if an approved drug acting on TRPM8 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.